|
|
|
%20BIOTECHNOLOGY%20CO%20,%20LTD%20%20-%20499821%2029-Mar-2018_files/image007.jpg){kind=small}
%20BIOTECHNOLOGY%20CO%20,%20LTD%20%20-%20499821%2029-Mar-2018_files/image008.jpg)
%20BIOTECHNOLOGY%20CO%20,%20LTD%20%20-%20499821%2029-Mar-2018_files/image010.gif)
MIRA INFORM REPORT
|
Report No. : |
499821 |
|
Report Date : |
29.03.2018 |
IDENTIFICATION DETAILS
|
Name : |
MOLBASE
(SHANGHAI) BIOTECHNOLOGY CO., LTD. |
|
|
|
|
Registered Office : |
Room 6020, Floor 6, Building 1, No. 399 North Fute Road, Pilot Free
Trade Zone, Shanghai |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2015 |
|
|
|
|
Date of Incorporation : |
14.05.2014 |
|
|
|
|
Com. Reg. No.: |
913100003016121743 |
|
|
|
|
Legal Form : |
Wholly Foreign-Owned Enterprise |
|
|
|
|
Line of Business : |
Subject registered business scope includes technology consulting and technology
services of biotechnology, new materials technology, chemical technology, environmental
technology, information technology, computer software and hardware
technology, electronic technology, communication technology; network
engineering design, computer systems integration; wholesale, import and
export, commission agents of general merchandise, apparel, leather products,
washing supplies, cosmetics, skin care products, photographic equipment,
toys, stationery, audio equipment, hardware, electronic products,
communication equipment, instrument and meter, auto accessories, welding equipment,
electrical equipment, wire and cable, electronic components, chemical
products; providing related supporting services, investment management. |
|
|
|
|
No. of Employees : |
321 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Slow but Correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would allow a resumption of gradual liberalization. From 2013 until early 2015, the renminbi (RMB) appreciated roughly 2% against the dollar, but the exchange rate fell 13% from mid-2015 until end-2016 amid strong capital outflows in part stemming from the August 2015 official devaluation; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF’s special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.
The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government’s policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.
|
Source
: CIA |
Company
Name And Address
|
COMPANY NAME |
Molbase (Shanghai) Biotechnology Co., Ltd. |
|
CURRENT ADDRESS |
5th Floor, Building 12, No. 1001 North
Qinzhou Road, Xuhui District, Shanghai 200233 PR China |
|
REGISTERED
ADDRESS |
Room 6020, Floor 6, Building 1, No. 399
North Fute Road, Pilot Free Trade Zone, Shanghai |
|
TEL.
NO. |
86 (0) 21-54365062/64956998 |
|
FAX
NO. |
86 (0) 21-54365166 |
EXECUTIVE
SUMMARY
Date of Registration : may 14, 2014
UNIFIED SOCIAL CREDIT CODE : 913100003016121743
LEGAL FORM : Wholly foreign-owned enterprise
REGISTERED CAPITAL : USD 24,000,000
staff : 321
BUSINESS CATEGORY : TRADING & SERVICES
Revenue : CNY 1,082,650,000 (AS OF DEC. 31, 2015)
EQUITIES : CNY 11,840,000 (AS OF DEC. 31, 2015)
WEBSITE : www.molbase.com
E-MAIL : service@molbase.com
PAYMENT : SLOW BUT CORRECT
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION :
FAIR
OPERATIONAL TREND :
FAIRLY STEADY
GENERAL REPUTATION :
AVERAGE
Adopted abbreviations (as follows)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL
TREND & GENERAL REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL
STATUS & HISTORY
SC was established
as wholly foreign-owned enterprise
of PRC with State Administration of Industry & Commerce (SAIC) under
Unified Social Credit Code: 913100003016121743.
SC’s Import and Export Enterprise
Code: 3100301612174
SC’s registered capital: USD 24,000,000
Registration Change Record:-
|
Date |
Change of Contents |
Before the change |
After the change |
|
|
Registered Capital |
USD 1,000,000 |
USD 3,000,000 |
|
|
Registered Capital |
USD 3,000,000 |
USD 6,000,000 |
|
|
Registration No./ Unified Social Credit Code |
310141400008243 |
913100003016121743 |
|
|
Registered Capital |
USD 6,000,000 |
USD 10,000,000 |
|
|
Registered Capital |
USD 10,000,000 |
USD 14,000,000 |
|
|
Registered Capital |
USD 14,000,000 |
USD 24,000,000 |
Current Co search indicates SC’s shareholders & chief executives
are as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
MOLBASE (HK) Limited |
100 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative, Chairman
and General Manager |
Chang
Dongliang |
|
Supervisor |
Wu
Zhengyu |
RECENT
DEVELOPMENT
No recent development was found during our checks at present.
SHAREHOLDER
CHART & BACKGROUND
Name %
of Shareholding
MOLBASE (HK) Limited 100
-----------------------------------
Date of Registration: February 14, 2014
CR No.: 2036753
Legal Form: Private
Status: Live
MANAGEMENT
Chang Dongliang , Legal
Representative, Chairman and General Manager
----------------------------------------------------------------------------------------------------------
Ø Gender: M
Ø Nationality: China
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as legal
representative, chairman and general manager
Also working in Molbase (Tianjin)
Biotechnology Co., Ltd., Shaanxi Molbase Biotechnology Co., Ltd. and Shanghai
Moyu Biotechnology Co., Ltd. as legal representative
Wu Zhengyu , Supervisor
--------------------------------------------
Ø
Gender: M
Ø
Nationality: China
Ø Qualification:
University
Ø Working experience
(s):
At present, as supervisor of SC
BUSINESS
OPERATION
SC’s registered business scope includes technology
consulting and technology services of biotechnology, new materials technology,
chemical technology, environmental technology, information technology, computer
software and hardware technology, electronic technology, communication
technology; network engineering design, computer systems integration;
wholesale, import and export, commission agents of general merchandise,
apparel, leather products, washing supplies, cosmetics, skin care products,
photographic equipment, toys, stationery, audio equipment, hardware, electronic
products, communication equipment, instrument and meter, auto accessories,
welding equipment, electrical equipment, wire and cable, electronic components,
chemical products; providing related supporting services, investment
management.
SC is
mainly engaged in selling chemicals, and providing services of chemical
information.
SC’s
products mainly include: Dimethylamide acetate, Dodecyl sulfate sodium salt,
THF, Ethanol, Talc, phenanthrene-9, Benzo, etc.
SC sources its products 80% from
domestic market, and 20% from overseas market. SC sells 60% of its products in
domestic market, and 40% to overseas market, mainly U.S.A., etc.
The
buying terms of SC include Check, T/T, L/C and Credit of 30-60 days. The
payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
*Major Customer*
=============
Curtume
Moderno Sa
Ennis
Paint Inc.
Pawan
Chemicals
Staff & Office:
--------------------------
SC is
known to have approx. 321
staff at present.
SC rents an area
as its operating office, but the detailed information is unknown.
RELATED
COMPANY
SC is known to
have 5 subsidiaries at present.
Hele
(Tianjin) Investment Management Co., Ltd.
Molbase
(Tianjin) Biotechnology Co., Ltd.
Shaanxi
Molbase Supply Chain Management Co., Ltd.
Shaanxi
Molbase Biotechnology Co., Ltd.
Shanghai
Moyu Biotechnology Co., Ltd.
PAYMENT
Overall payment appraisal:
( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment records and our debt collection record
concerning SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent payment record: None in our
database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
Basic Bank:
China
Merchants Bank Shanghai Pudong New Area Waigaoqiao Sub-branch
AC#:
121912567210902
FINANCIALS
Balance Sheet
|
Unit: CNY’000 |
As
of Dec. 31, 2015 |
|
6,300 |
|
|
Notes receivable |
1,130 |
|
Accounts
receivable |
36,810 |
|
Advances to
suppliers |
99,640 |
|
Other receivable |
1,920 |
|
Inventory |
20,140 |
|
Non-current
assets within one year |
0 |
|
Other current
assets |
0 |
|
|
------------------ |
|
Current assets |
165,940 |
|
Fixed assets |
960 |
|
Construction in
progress |
0 |
|
Intangible
assets |
100 |
|
Long-term
deferred expenses |
700 |
|
Deferred income
tax assets |
0 |
|
Other
non-current assets |
0 |
|
|
------------------ |
|
Total assets |
167,700 |
|
|
============= |
|
Short-term loans |
0 |
|
Notes payable |
0 |
|
Accounts payable |
28,830 |
|
Payroll payable |
150 |
|
Taxes payable |
-2,300 |
|
Advances from
clients |
78,810 |
|
Other payable |
49,430 |
|
Other current liabilities |
940 |
|
|
------------------ |
|
Current
liabilities |
155,860 |
|
Non-current
liabilities |
0 |
|
|
------------------ |
|
Total
liabilities |
155,860 |
|
Equities |
11,840 |
|
|
------------------ |
|
Total
liabilities & equities |
167,700 |
|
|
============= |
Income Statement
|
Unit: CNY’000 |
As of Dec. 31,
2015 |
|
Revenue |
1,082,650 |
|
Cost of sales |
1,075,520 |
|
Sales expense |
7,350 |
|
Management expense |
20,000 |
|
Finance expense |
-320 |
|
Non-operating
income |
40 |
|
Non-operating expense |
0 |
|
Profit before
tax |
-19,860 |
|
Less: profit tax |
0 |
|
-19,860 |
Important Ratios
=============
|
|
As of Dec. 31, 2015 |
|
*Current ratio |
1.06 |
|
*Quick ratio |
0.94 |
|
*Liabilities
to assets |
0.93 |
|
*Net profit
margin (%) |
-1.83 |
|
*Return on
total assets (%) |
-11.84 |
|
*Inventory /
Revenue ×365 |
6 days |
|
*Accounts
receivable / Revenue ×365 |
12 days |
|
*Revenue /
Total assets |
6.46 |
|
*Cost of sales
/ Revenue |
0.99 |
FINANCIAL
COMMENTS
PROFITABILITY:
FAIR
l The revenue of SC appears fairly good in its line.
l SC’s net profit
margin is fair.
l SC’s return on
total assets is fair.
l
SC’s cost of sales is high, comparing with its revenue.
LIQUIDITY:
AVERAGE
l
The current ratio of SC is maintained in a normal
level.
l
SC’s quick ratio is maintained in a normal level.
l
The inventory of SC appears average.
l
The accounts receivable of SC appears average.
l
SC has no short-term loans
l
SC’s revenue is in an average
level, comparing with the size of its total assets.
LEVERAGE:
AVERAGE
l
The debt ratio of SC is high.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fair.
CONCLUSIONS
SC is considered medium-sized in its line with
fair financial conditions
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 65.04 |
|
|
1 |
INR 92.28 |
|
Euro |
1 |
INR 80.62 |
|
CNY |
1 |
INR 10.36 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VIV |
|
|
|
|
Report Prepared
by : |
KET |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.